文献速递眼底病与葡萄膜炎

玻璃体腔抗VEGF治疗增殖性糖尿病视网膜病变累及黄斑的牵拉性视网膜脱离

Treatment of foveal-involving tractional retinal detachments from proliferative diabetic retinopathy with intravitreal anti-VEGF therapy.
PubMed 文献 · Retina · 2026-08-31

本回顾性病例系列纳入10例患者12只眼,评估系列玻璃体腔抗VEGF治疗增殖性糖尿病视网膜病变所致黄斑区脱离的牵拉性视网膜脱离的疗效。75%眼(9只眼)单用抗VEGF实现黄斑复位,平均用时15个月,平均注射7次、间隔2.3个月;视力在6、12个月及末次随访时呈稳定或改善趋势。

要点

  • 黄斑区脱离的牵拉性视网膜脱离中,75%眼可单用系列抗VEGF实现黄斑复位。
  • 复位者平均注射7次、平均间隔2.3个月,诊断至复位平均15个月。
  • 平均logMAR视力从初诊1.79改善至末次随访1.36,复位者达1.01。

核心结论

  • 对增殖性糖尿病视网膜病变所致黄斑区脱离的牵拉性视网膜脱离,系列玻璃体腔抗VEGF治疗可观察到视力和解剖稳定,部分病例改善。

研究设计与样本

  • 回顾性病历复习,纳入10例患者共12只眼,均因增殖性糖尿病视网膜病变出现黄斑区脱离的牵拉性视网膜脱离并接受系列玻璃体腔抗VEGF治疗。

主要发现

  • 75%的眼(9只眼)单用抗VEGF治疗实现黄斑复位,从诊断到黄斑复位平均15个月。
  • 实现黄斑复位的9只眼平均接受7次注射,平均注射间隔2.3个月。
  • 初诊平均logMAR视力1.79(Snellen约20/1233),6个月1.6(20/790),12个月1.4(20/466)。
  • 末次随访平均27.8个月时,全部患者平均logMAR视力1.36(20/453),黄斑复位者1.01(20/204)。

临床怎么用

  • 对增殖性糖尿病视网膜病变所致黄斑区脱离的牵拉性视网膜脱离,可考虑系列玻璃体腔抗VEGF治疗作为保留或改善视力的选择。

局限性

  • 回顾性设计、样本量小(12只眼),未设对照组,结果需更大样本研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the outcomes of patients with fovea-off tractional retinal detachment (TRD) from proliferative diabetic retinopathy (PDR) treated with serial anti-VEGF therapy. METHODS: We reviewed the medical records of patients with fovea-off TRD from PDR treated with serial anti-VEGF therapy. Outcome measures included visual acuity, foveal reattachment, need for vitrectomy, number of intravitreal injections, and average interval between injections. RESULTS: 12 eyes of 10 patients were included. 75% of eyes (n = 9) had foveal reattachment with anti-VEGF therapy alone. The average time from TRD diagnosis to foveal reattachment was 15 months. Patient who experienced foveal reattachment (n = 9) received an average of 7 injections with an average injection interval of 2.3 months. At presentation, mean logMAR VA was 1.79 (Snellen visual acuity equivalent 20/1233). At 6 months, mean logMAR VA was 1.6 (20/790), and at 12 months, mean logMAR VA was 1.4 (20/466). At a last follow-up (mean 27.8 months), mean logMAR VA was to 1.36 (20/453) among all patients and 1.01 (20/204) among patients who had foveal reattachment. CONCLUSION: In this cohort of eyes treated with intravitreal anti-VEGF for fovea-off TRD from PDR retinopathy, we observed visual and anatomic stability, and, in some cases, improvement.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Mehta N, Hubbard GB. Treatment of foveal-involving tractional retinal detachments from proliferative diabetic retinopathy with intravitreal anti-VEGF therapy. Retina. 2026. PMID: 42671892. doi:10.1097/IAE.0000000000005004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。